Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q15858: Variant p.Asn641Tyr

Sodium channel protein type 9 subunit alpha
Gene: SCN9A
Feedback?
Variant information Variant position: help 641 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Asparagine (N) to Tyrosine (Y) at position 641 (N641Y, p.Asn641Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (N) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Found in patients with febrile seizures plus; uncertain significance. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 641 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1988 The length of the canonical sequence.
Location on the sequence: help AVDCNGVVSLVDGRSALMLP N GQLLPEVIIDKATSDDSGTT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         AVDCNGVVSLVDGRSALMLPNGQLLPEVIIDKATSDDSGTT

Mouse                         AVDCNGVVSLVDGPSALMLPNGQLLPEVIIDKATSDDSGTT

Rat                           AVDCNGVVSLVDGPSALMLPNGQLLPEVIIDKATSDDSGTT

Rabbit                        AVDCNGVVSLVDGPSALMLPNGQLLPEVIIDKATSDDSGTT

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1988 Sodium channel protein type 9 subunit alpha
Topological domain 400 – 744 Cytoplasmic



Literature citations
A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.
Singh N.A.; Pappas C.; Dahle E.J.; Claes L.R.; Pruess T.H.; De Jonghe P.; Thompson J.; Dixon M.; Gurnett C.; Peiffer A.; White H.S.; Filloux F.; Leppert M.F.;
PLoS Genet. 5:E1000649-E1000649(2009)
Cited for: VARIANTS VAL-62; GLN-149; MET-228; ASN-490; LYS-519; TYR-641; ARG-666; MET-695; TYR-710; VAL-750; PHE-1134; GLN-1171 AND VAL-1278; No association between SCN9A and monogenic human epilepsy disorders.
Fasham J.; Leslie J.S.; Harrison J.W.; Deline J.; Williams K.B.; Kuhl A.; Scott Schwoerer J.; Cross H.E.; Crosby A.H.; Baple E.L.;
PLoS Genet. 16:e1009161-e1009161(2020)
Cited for: LACK OF INVOLVEMENT IN EPILEPSY AND FEBRILE SEIZURES; VARIANT TYR-641;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.